Dexcom International Ltd is the European arm of Dexcom, a global leader in diabetes care technology, specializing in continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, with its EU and UK offices based in Edinburgh, United Kingdom, Dexcom empowers individuals with diabetes to manage their condition more effectively through innovative health technology solutions. Since its registration with the EU Transparency Register on June 16, 2020, Dexcom International Ltd has been actively engaged in advocating for regulatory frameworks that support the advancement and accessibility of CGM and related medical technologies across the European Union.
Dexcom’s lobbying activities focus on influencing EU policy and legislation in areas such as the European Health Data Space, the AI Act, and broader regulations related to medical devices, data protection, and digital health. The company’s approach is rooted in its mission to simplify and improve diabetes management by ensuring that regulatory environments foster innovation, interoperability, and patient access to advanced CGM systems.
The firm’s EU lobbying efforts are characterized by a measured and compliant approach, with declared lobbying costs and transparent reporting of its activities. Dexcom International Ltd is a member of MedTech Europe, the leading European medical technology industry association, and participates in relevant discussions and consultations primarily as part of this collective. The company’s activities are focused on promoting its own interests and those of its sector, rather than direct engagement with high-level EU officials or parliamentary groups.
Dexcom’s lobbying is conducted by a small, dedicated team, with no individuals holding European Parliament accreditation. The company has not declared any high-level Commission meetings or direct communication activities as an individual entity, instead contributing to sectoral advocacy through its industry association. Financial disclosures indicate a consistent investment in lobbying activities, with costs covering both internal staff time and association membership fees.
Overall, Dexcom International Ltd’s profile in the EU lobbying landscape is that of a specialized, sector-focused company working to ensure that EU health and digital policies support the continued innovation and adoption of life-changing diabetes technologies
